Osteoprotegerin, RANK, and RANK ligand: The good, the bad, and the ugly in rheumatoid arthritis: Editorial

Journal of Rheumatology

Volumn 28, Issue 4, 2001, Pages 685-687

  Hofbauer, L C ^a   Heufelder, A E ^a   Erben, R G ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CYTOKINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECOMBINANT HUMAN OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; BONE EROSION; BONE METABOLISM; EDITORIAL; FIBROBLAST; HUMAN; IMMUNE SYSTEM; JOINT DESTRUCTION; NONHUMAN; OSTEOCLAST; OSTEOPOROSIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIDE EFFECT; T LYMPHOCYTE;

ANIMALS; ARTHRITIS, RHEUMATOID; CARRIER PROTEINS; GLYCOPROTEINS; HUMANS; MEMBRANE GLYCOPROTEINS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 0035078768     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (20)

1. Rheumatoid arthritis. Pathophysiology and implications for therapy
2. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families
3. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
4. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis inhibitory factor and is identical to TRANCE/RANKL
5. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-jun N-terminal kinase in T cells
6. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function
7. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand
8. Activated T cells support osteoclast formation in vitro
9. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density
10. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro
11. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts
12. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
13. Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis
14. IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosions
15. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor
16. Involvement of receptor activator of nuclear factor κB ligand osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis
17. Increase of bone mineral density and anabolic variables in patients with rheumatoid arthritis resistant to methotrexate after cyclosporin A therapy
18. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis
19. Arthritis patterns in rats with adjuvant-induced arthritis define distinct mechanisms of joint protection for IL-Ira, sTNF RI, and OPG
20. Osteoprotegerin has potent and sustained anti-resorptive activity in postmenopausal women